CD8A and cancer: Anti-PD-1 antibodies, such as Nivolumab and Pembrolizumab, selectively target the interaction between PD-1 receptors on CD8+ T cells and its ligands PD-L1/PD-L2 expressed by cancer cells, resulting in the abolishment of the inhibition of the CD8+ T cells and the restoration of antitumor activity [19,20].